| Name | Title | Contact Details |
|---|
Turn 14 Distribution is a Performance Warehouse Distributor with distribution facilities strategically located in Hatfield, PA, Arlington, TX, Reno, NV, and Indianapolis, IN. Turn 14 Distributions strategy consists of catering to niche vehicle markets, along with stocking its partner manufacturers full product lines for quick order fulfillment. Exclusive Turn 14 Distribution promotions ensure that products are marketed efficiently and correctly to each suppliers target audience. The company relies upon its dedicated sales specialists—chosen for their experience in each particular market—to service its customers with superior knowledge. In addition, the companys website offers lens technology to permit customers to view the products available for each individual market most efficiently. Turn 14 Distributions up-to-the-minute online inventory tracking, efficient forecasting, and dedicated Customer Support Department allow the company to cut lead times and keep its customers informed about product fulfillment. The companys goal is to provide its customers the sales, marketing, and post-sales support needed to succeed in the modern marketplace. With 1,500,000 sq ft of modern distribution center space, Turn 14 Distribution boasts ground shipping coverage to 60% of the U.S. population in one day and 100% within two days. Globally, Turn 14 Distributions competitive freight rates, ship to your shop flat rate shipping, late shipping cutoff times, seven-day-a-week operation, and same day in-stock order fulfillment commitment enable it to service customers both across the United States and the world efficiently.
After driving growth for my third VC-backed exit, Andrew Lee Miller (@andrewstartups) founded GrowthExpertz, a unique growth agency focused solely on helping tech startups in their first 12-24 months post-funding. Since 2016 weve helped over a dozen startups get to 8-9 figure valuation, several exits, and almost 100 total successful projects. We specialize in full-stack growth, handled remotely by expertz, for companies that have raised capital but still need help with marketing. We work in the background to strategize, launch and scale their organic and paid campaigns while they handle everything else. Some notable clients: www.datadistillr.com (raised $10m off of our work) www.canweapp.com (exited) www.withdouble.com (grew 30% in first 3 months) www.getemails.com (now retention.com doing $30m ARR) www.CrownDating.com (exit to Tinder/Match Group) www.denizen.io (BBVA Incubator) www.zedge.net (100m+ installs) www.different.com.au (now one of the largest startups in Australia) www.fly.com (300% increase in traffic in 12 months) www.openinvest.co (acquired by Chase) We are industry agnostic but often focus on SaaS, Fintech, Marketplace, Online Dating, Consumer Mobile Apps, and more. Email contact@growthexpertz.com or book a call at www.growthexpertz.com
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.